ArticleJournal of clinical microbiology2002
Production of BRO beta-lactamases and resistance to complement in European Moraxella catarrhalis isolates.
Article in Journal of clinical microbiology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Carriage epidemiology of Moraxella catarrhalis in an all-age community cohort between 2016 and 2018.Access microbiology · 2026Article
- Systems perspectives on pediatric otitis media: environmental exposures, genetic susceptibility, and biomarker-guided interventions.Frontiers in pediatrics · 2026Review
- A global perspective on the genomics ofMicrobial genomics · 2025Article
- The burden of antibiotic resistance of the main microorganisms causing infections in humans - review of the literature.Journal of medicine and life · 2024Review
- Moraxella Bacteremia in Cancer Patients.Cureus · 2021Article
- Characterization of antibiotic resistance and host-microbiome interactions in the human upper respiratory tract during influenza infection.Microbiome · 2020Article
- Molecular Characterization of Fluoroquinolone-Resistant Moraxella catarrhalis Variants GeneratedAntimicrobial agents and chemotherapy · 2017Article
- Prevalence and resistance pattern of Moraxella catarrhalis in community-acquired lower respiratory tract infections.Infection and drug resistance · 2015Article
- Moraxella catarrhalis uses a twin-arginine translocation system to secrete the β-lactamase BRO-2.BMC microbiology · 2013Article
- Article
- Hag mediates adherence of Moraxella catarrhalis to ciliated human airway cells.Infection and immunity · 2009Article
- Bactericidal monoclonal antibody against Moraxella catarrhalis lipooligosaccharide cross-reacts with Haemophilus Spp.Current microbiology · 2007Article
- The UspA2 protein of Moraxella catarrhalis is directly involved in the expression of serum resistance.Infection and immunity · 2005Article
- Presumed endocarditis caused by BRO beta-lactamase-producing Moraxella lacunata in an infant with Fallot's tetrad.Journal of clinical microbiology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Of the 419 Moraxella catarrhalis isolates collected during the 1997-1999 European SENTRY surveillance study, 385 (92%) were beta-lactamase positive. Twenty-two (5.7%) produced BRO-2 beta-lactamase. Twenty-one new mutations were found in the putative promoter region of the bro genes. Nineteen percent of all isolates tested were complement sensitive. Resistance to beta-lactams is not linked to the phylogenetic lineages associated with susceptibility to complement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.